343 results on '"Ghezzi, Angelo"'
Search Results
2. Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment
3. Correction: Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis: A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment
4. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study
5. Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset
6. Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials
7. Correction to: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing–Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSII Trials
8. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting
9. Aging with multiple sclerosis: prevalence and profile of cognitive impairment
10. The Italian multiple sclerosis register
11. European and American Guidelines for Multiple Sclerosis Treatment
12. Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
13. Different MRI patterns in MS worsening after stopping fingolimod
14. Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5-year MRI study
15. Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®
16. Cognitive assessment in multiple sclerosis—an Italian consensus
17. Neurofilament Light Chain in Adult and Pediatric Multiple Sclerosis:A Promising Biomarker to Better Characterize Disease Activity and Personalize MS Treatment
18. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
19. A Comprehensive Review on Copemyl®
20. Correction to: Aging with multiple sclerosis: prevalence and profile of cognitive impairment
21. Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
22. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks
23. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks
24. Long-term disability progression in primary progressive multiple sclerosis: a 15-year study
25. MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients
26. Correction to: Cognitive assessment in multiple sclerosis—an Italian consensus
27. Correction to: The Italian multiple sclerosis register
28. Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years
29. Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study
30. Abnormalities of the executive control network in multiple sclerosis phenotypes: An fMRI effective connectivity study
31. Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEQ-IT)
32. Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire)
33. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis
34. Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening
35. sj-docx-1-mso-10.1177_20552173211059048 - Supplemental material for Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire)
36. sj-docx-2-mso-10.1177_20552173211059048 - Supplemental material for Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire)
37. The introduction of new medications in pediatric multiple sclerosis:Open issues and challenges
38. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
39. Identifying distinct cognitive phenotypes in multiple sclerosis (4284)
40. Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis
41. The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial)
42. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS : Practical considerations
43. Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening.
44. In vivo gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology
45. Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
46. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study
47. Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations
48. The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges
49. Changes in Management of Pediatric-onset Multiple Sclerosis: Are We Really Modifying the Disease Course? Data from the Italian MS Registry (3938)
50. Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.